MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 46 - per page Next page
Order by
5 and 10 mg Donepezil as well as 4 and 8 mg Ondansetron are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Glutaminyl Cyclase (QC) is an enzyme responsible for pyroglutamate formation of beta amyloids peptides. Inhibition of QC activity can potentially act as an AD therapy or even prevention as plaque cores consist entirely of pyroglutamated beta amyloids More
5 and 10 mg Donepezil are under final development using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
The measurement of GSK-3 in circulating white cells is a useful early diagnostic marker and potential therapy for Alzheimer's Disease. More
A non-transgenic, adult onset rodent model for Alzheimer's disease and stroke. More
Colorless molecule that will bind and enhance the differential surface charge on protein complexes: The molecule has been demonstrated to work as well as Coomassie blue but will not interfere in gel assays critical for most investigations. More
Our US based client established a company based on research from a US University that quantifies a unique protein/protein complex in cerebrospinal fluid (CSF) and serum that identifies AD subjects including those early in disease progression. More
These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). More
These analogs may increase water solubility and bioavailability for improved therapeutic formulation and utility More
Displaying 1..10 of 46 - per page Next page
Order by

Your selection

Therapeutic target
Central Nervous System del
Neurodegenerative disorders del
Alzheimer's disease del

Browse By

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us